{"id":3430,"date":"2026-09-24T09:00:00","date_gmt":"2026-09-24T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3430"},"modified":"2026-09-24T21:21:35","modified_gmt":"2026-09-25T01:21:35","slug":"miv-cel-responses-persist-at-one-year","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3430","title":{"rendered":"Miv-cel Responses Persist at One Year"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Kyverna Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Trial Durability Data<\/p>\n

Modality<\/strong><\/p>\n

CAR-T Cell Therapy (CD19-Directed)<\/p>\n

Asset<\/strong><\/p>\n

Mivocabtagene Autoleucel (Miv-cel)<\/p>\n

Target<\/strong><\/p>\n

CD19<\/p>\n

Disease Area<\/strong><\/p>\n

Stiff Person Syndrome \/ Generalized Myasthenia Gravis<\/p>\n

Summary<\/h4>\n

Kyverna reported 12-month durability from the 26-patient KYSA-8 registrational study in stiff person syndrome and longer follow-up from seven generalized myasthenia gravis patients. Median timed 25-foot walk improvement in SPS was 49% at Month 12, 92% remained free of chronic SPS immunotherapy, and no high-grade cytokine-release syndrome, ICANS or IEC-HS was reported. A rolling SPS BLA remains targeted for completion in the fourth quarter of 2026.<\/p>\n

In KYSA-8, 95% of patients who achieved a clinically meaningful walking-speed improvement at the primary analysis maintained it at Month 12. Eight of 12 patients who required walking assistance before treatment reportedly remained independent of it. Secondary disability, stiffness, sensitivity and mobility measures also remained improved, although full distributions and patient-level trajectories were not disclosed.<\/p>\n

In the seven-patient Phase 2 gMG cohort, mean 24-week MG-ADL and QMG changes were -8.3 and -11.7 points. Five patients have reached at least one year, with reported maintenance of clinically meaningful improvement; four of seven had minimal symptom expression at last follow-up and six of seven remained off immunosuppressants.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation one is that deep CD19-positive B-cell depletion produced a durable immune reset. Persistence across disease measures and reduced immunotherapy use support more than a transient peri-treatment effect. Against it, KYSA-8 is single-arm, susceptible to expectation, rehabilitation and regression effects, and detailed steroid or rescue-therapy histories are not public.<\/p>\n

Interpretation two is that miv-cel may have a favorable neurologic-autoimmune safety profile relative to some CAR T experiences. The absence of high-grade CRS, ICANS and IEC-HS is supportive, but 26 SPS and seven gMG patients cannot exclude uncommon neurotoxicity, infection, cytopenia or delayed immune complications. Regulatory confidence will depend on endpoint robustness, missing-data handling, manufacturing consistency and whether functional gains exceed credible natural-history variability. Controlled Phase 3 gMG data and full SPS BLA review could upgrade the interpretation; loss of benefit, late safety events or discordant blinded assessment would weaken it.<\/p>\n

Company and Product Background<\/h4>\n

Kyverna’s mivocabtagene autoleucel is an autologous CD19-directed CAR T cell with CD28 costimulation. It is intended to remove autoreactive B-cell compartments deeply enough to permit immune reconstitution without continued immunosuppression. SPS produces progressive rigidity, spasm and mobility loss, often with GAD65 or glycine-receptor antibodies; gMG is an antibody-mediated neuromuscular-junction disorder.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • SPS: 26 treated patients with 12-month follow-up.<\/li>\n
  • Mobility: median T25FW improvement 49% at Month 12; 95% durability among initial responders.<\/li>\n
  • Treatment burden: 92% off chronic SPS immunotherapy.<\/li>\n
  • gMG: seven patients; five followed at least one year; 57% minimal symptom expression at last follow-up.<\/li>\n
  • Safety claim: no high-grade CRS, ICANS or IEC-HS in the disclosed cohorts.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The durability signal is clinically important and directionally positive, especially in a progressive disease without an approved therapy. Causation is less secure than the headline suggests because SPS lacks a randomized control and the gMG cohort is very small. The report therefore treats “immune reset” and “disease-free remission” as hypotheses rather than established outcomes.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: high for the company-reported topline dataset and SEC-filed disclosure. Confidence in Interpretation: moderate because SPS lacks a concurrent control and gMG includes seven patients.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Kyverna reported 12-month durability from the 26-patient KYSA-8 registrational study in stiff person syndrome and longer follow-up from seven generalized myasthenia gravis patients. Median timed 25-foot walk improvement in SPS was 49% at Month…<\/p>\n","protected":false},"author":1,"featured_media":3441,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[861,860,859],"class_list":["post-3430","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-kyverna-therapeutics","tag-myasthenia-gravis","tag-stiff-person-syndrome"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3430"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3430\/revisions"}],"predecessor-version":[{"id":3450,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3430\/revisions\/3450"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3441"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}